Top analyst pokes hole in AstraZeneca/Oxford data while scientists tamper hope for fast rollout

AstraZeneca and Oxford may have outshone Pfizer and BioNTech — at least in terms of media attention — with Phase I results on its Covid-19 vaccine initially. But a closer look suggests the adenovirus-based candidate doesn’t exactly match the bar set by mRNA vaccines on offer, including one from Moderna.